Send to:

Choose Destination
See comment in PubMed Commons below
Target Oncol. 2009 Dec;4(4):255-66. doi: 10.1007/s11523-009-0123-z. Epub 2009 Oct 30.

Targeting insulin-like growth factor type 1 receptor in cancer therapy.

Author information

  • 1Department of Medical Oncology, University of Cagliari, 09042, Cagliari, Italy.


It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk